{
    "relation": [
        [
            "",
            "EFV+ddI+FTC in Infants >=3 Months to < 6 Months",
            "EFV+ddI+FTC in Infants >=6 Months to < 2 Years",
            "EFV+ddI+FTC in Children >= 2 Years to < 3 Years",
            "EFV+ddI+FTC in Children >= 3 Years to <= 6 Years",
            "EFV+ddI+FTC in All Participants"
        ],
        [
            "Description",
            "EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle (eg, yogurt, applesauce, or grape jelly), or oral solution (30 mg/mL). In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.",
            "EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle (eg, yogurt, applesauce, or grape jelly), or oral solution (30 mg/mL). In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.",
            "EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle (eg, yogurt, applesauce, or grape jelly), or oral solution (30 mg/mL). In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.",
            "EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle (eg, yogurt, applesauce, or grape jelly), or oral solution (30 mg/mL). In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg.",
            "All participants across all age groups, ie greater than, equal to 3 months to less than, equal to 6 years who received study drug. EFV (efavirenz) was administered in accordance with weight-based dosing nomograms and included one of the following preparations in a once a day (QD) dose: EFV capsules (50 and 200 mg) contents mixed with formula or a small amount of food vehicle (eg, yogurt, applesauce, or grape jelly), or oral solution (30 mg/mL). In addition, the following 2 drugs were administered: ddI (didanosine) (Pediatric Powder for Oral Solution or capsules of enteric-coated beads): 240 mg/m^2 QD; maximum daily dose of 400 mg and FTC (emtricitabine) (solution or tablets) 6 mg/kg QD; maximum daily dose of 240 mg."
        ]
    ],
    "pageTitle": "Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00364793?sect=Xk0156&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042986646.29/warc/CC-MAIN-20150728002306-00076-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 862296619,
    "recordOffset": 862280142,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups 56 participants were enrolled but 19 were never treated. Reasons for not treating: 2 deaths, 1 lost to follow up, 6 other (not specified), 9 no longer met study criteria, 1 withdrew consent. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details This study initiated February 2007 and completed July 2013. All participants enrolled in countries where efavirenz (EFV) oral solution was not commercially available could remain on study until their 7th birthday or until they were able to swallow EFV capsules (whichever occurred first). Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC) Intervention: HIV",
    "textAfterTable": "\u00a0 \u00a0 EFV+ddI+FTC in Infants >=3 Months to < 6 Months \u00a0 \u00a0 EFV+ddI+FTC in Infants >=6 Months to < 2 Years \u00a0 \u00a0 EFV+ddI+FTC in Children >= 2 Years to < 3 Years \u00a0 \u00a0 EFV+ddI+FTC in Children >= 3 Years to <= 6 Years \u00a0 STARTED \u00a0 \u00a0 15 \u00a0 \u00a0 10 \u00a0 \u00a0 4 \u00a0 \u00a0 8 \u00a0 COMPLETED \u00a0 \u00a0 7 \u00a0 \u00a0 5 \u00a0 \u00a0 0 \u00a0 \u00a0 5 \u00a0 NOT COMPLETED \u00a0 \u00a0 8 \u00a0 \u00a0 5 \u00a0 \u00a0 4 \u00a0 \u00a0 3 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 2 \u00a0 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}